Lilly to slash 1,624 sales jobs in stepped-up layoff plan

Tracy Staton As the Indianapolis Business Journal reports, the drugmaker now plans to eliminate 1,624 sales positions, rather than the "fewer than 1,000" cuts previously announced. ...

Baxter adds Gammagard to growing roster of Ph III Alzheimer’s failures

John Carroll The long and frustrating search for something–anything–that can treat Alzheimer's or blunt its symptoms ran into yet another Phase III roadblock this morning ...

Celgene nabs another round of promising pivotal apremalist data for psoriatic arthritis

John Carroll FierceBiotech News

Merck wins FDA nod for new Zetia-Lipitor combo, despite lack of outcomes benefit

Tracy Staton Merck will soon launch a new cholesterol combo that melds its Zetia drug with generic Lipitor. The Zetia-plus-statin approach isn't new, of course; Merck already sells ...

Covidien predicts up to 11% sales growth at soon-to-be independent Mallinckrodt unit

Tracy Staton Covidien unveiled its forecast for Mallinckrodt, the drug unit it plans to set free later this year. Percentage-wise, the expectations are strong: For the fiscal year ending ...

Celgene turns to Concert for $300M deuterium-tweaking cancer collaboration

John Carroll Concert Pharma CEO Roger Tung has reeled in his third collaboration deal in a little more than a year, inking a $ 300 million pact with Celgene to tweak cancer and anti-inflammatory ...

Minority Schering shareholders extract another €46 per share from Bayer

Eric Palmer A group of minority Schering AG shareholders held out to the bitter end against what Bayer wanted to pay them for their shares, and they will now get the sweet deal they ...

Bristol-Myers, AstraZeneca report positive data for rare metabolic disease drug

John Carroll The treatment, under review at the FDA, was acquired by Bristol-Myers Squibb as part of its $ 5.3 billion acquisition of Amylin last year and swiftly partnered with AstraZeneca ...

J&J’s propofol administration device finally wins FDA nod

Tracy Staton Johnson & Johnson won FDA approval for its Sedasys device to administer the sedative propofol. FiercePharma News

Johnson & Johnson, Pfizer target painkiller revivals as FDA warms to abuse deterrents

Ryan McBride The FDA has fueled a pharmaceutical arms race in the painkiller market with the agency's decision last month to bar the sale and production of generic OxyContin, which ...

Indian watchdogs pull J&J plant’s license on baby-powder sterilization issue

Tracy Staton South Korean regulators have forced Johnson & Johnson to halt production at an over-the-counter drug plant, and Indian watchdogs are doing the same at a consumer healthcare ...

NeuroPhage banks $6.4M for Alzheimer’s drug development effort

John Carroll A little more than two years after announcing a $ 12.4 million round to finance early-stage efforts on its experimental therapy for Alzheimer's, Cambridge, MA-based ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS